Tardive Dyskinesia Drug Safe, Effective for Huntington's Chorea Tardive Dyskinesia Drug Safe, Effective for Huntington's Chorea
Valbenazine is effective in improving symptoms of chorea for patients with Huntington ' s disease, without any increase in suicidal ideation or suicidal behavior, phase 3 trial results show.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 19, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Novel Drug Significantly Reduces Tics ― Without Side Effects Novel Drug Significantly Reduces Tics ― Without Side Effects
A drug with a novel mechanism of action reduces tics and does not cause weight gain or tardive dyskinesia ― side effects that are associated with current medications for the disorder.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 31, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
PolyCore Therapeutics raises $4.7M from investors
A Philadelphia biopharmaceutical company working on developing treatments for neurodegenerative disorders has raised $4.7 million in an equity financing deal. PolyCore Therapeutics is developing therapies for patients suffering from dyskinesia, a condition characterized by involuntary and erratic movements of the face, arms, legs or trunk, and from cognitive impairment. The company's lead new drug candidate, PCT-3012, is a small molecule drug being dev eloped to treat motor impairment in patients… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 22, 2022 Category: American Health Authors: John George Source Type: news
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Guidance Provided for Telepsychiatry in Tardive Dyskinesia Guidance Provided for Telepsychiatry in Tardive Dyskinesia
Tardive dyskinesia can be reasonably managed through telemedicine, but should be employed as part of a hybrid strategy that includes an office visit at time of diagnosis, experts say.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 25, 2021 Category: Neurology Tags: Psychiatry News Source Type: news
Mechanism of abnormal movements induced by drug treatment of Parkinson's disease
(National Institutes of Natural Sciences) Researchers at the National Institute for Physiological Sciences in Japan reveal the mechanism of hyperkinetic movements called L-DOPA-induced dyskinesia, which is a major side effect of medication in Parkinson's disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 7, 2021 Category: Biology Source Type: news
A child who suddenly freezes while trying to cross crosswalks-unique clinical manifestation of paroxysmal kinesigenic dyskinesia: a case report - Kim SY, Ahn JY, Kwak S, Chang MC.
We report the case of a patient with a unique clinical presentation of inability to cross crosswalks due to paroxysmal kinesigenic dyskinesia (PKD). (2) Case presentation: A 14-year-old boy presented with the inability to move his right leg... (Source: SafetyLit)
Source: SafetyLit - December 21, 2020 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
Man-machine interaction-based motion control of a robotic walker - Zhang C, Guo S, Xi FJ.
BACKGROUND: The aging population brings the problem of healthcare and dyskinesia. The lack of mobility extremely affects stroke patient's activities of daily living (ADL) and decreases their quality of life. To assist these mobility-limited people, a robot... (Source: SafetyLit)
Source: SafetyLit - October 27, 2020 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news
Sudden cardiac death after robbery: homicide or natural death? - Bottari G, Trotta S, Marzullo A, Meliota G, Ciccone MM, Solarino B.
Tako-Tsubo is one of a number of rare acquired cardiomyopathies that are characterized by left ventricular dyskinesia and symptomatology typical of acute myocardial infarction (AMI). The most important feature is that the clinical features are triggered by... (Source: SafetyLit)
Source: SafetyLit - September 21, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Parkinson's dyskinesia mechanism explained
(Scripps Research Institute) The mechanism underlying Parkinson's dyskinesia has been unknown, until now. An international collaboration led by Scripps Research, Florida has found a key cause, and with it, potentially, a new route to providing relief. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2020 Category: International Medicine & Public Health Source Type: news
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS(R) (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
ONGENTYS, the First and Only Approved Once-Daily COMT Inhibitor, Decreases "Off" Time and Increases "On" Time Without Troublesome Dyskinesia When Added to Levodopa/Carbidopa in Patients with Parkinson's Disease Neurocrine Biosciences... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, ONGENTYS, opicapone, Parkinson's Disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 27, 2020 Category: Pharmaceuticals Source Type: news
Image of the Day: Defective Cilia
Super-resolution imaging identifies abnormalities in the hair-like protrusions on a cell's surface and may help facilitate earlier detection of primary ciliary dyskinesia. (Source: The Scientist)
Source: The Scientist - April 7, 2020 Category: Science Tags: Image of the Day Source Type: news
What Are Some Risk Factors for Cerebral Palsy?
Discussion The term, cerebral palsy, or CP has gone through many iterations with the first description in 1861 by W.J. Little who described it as “The condition of spastic rigidity of the limbs of newborn children.” The most recent definition is from Rosenbaun et al. in 2007 which states it is “a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cog...
Source: PediatricEducation.org - March 9, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news